APA (7th ed.) Citation

Armstrong, A. W., Kircik, L., Stein Gold, L., Strober, B., De Oliveira, C. H. M. C., Vaile, J., . . . Lebwohl, M. (2025). Deucravacitinib: Laboratory Parameters Across Phase 3 Plaque Psoriasis Trials. Dermatology & Therapy, 15(4), 1025. https://doi.org/10.1007/s13555-025-01362-w

Chicago Style (17th ed.) Citation

Armstrong, April W., et al. "Deucravacitinib: Laboratory Parameters Across Phase 3 Plaque Psoriasis Trials." Dermatology & Therapy 15, no. 4 (2025): 1025. https://doi.org/10.1007/s13555-025-01362-w.

MLA (9th ed.) Citation

Armstrong, April W., et al. "Deucravacitinib: Laboratory Parameters Across Phase 3 Plaque Psoriasis Trials." Dermatology & Therapy, vol. 15, no. 4, 2025, p. 1025, https://doi.org/10.1007/s13555-025-01362-w.